drugset / Trial / NCT00849030

ATAC - Arimidex, Tamoxifen Alone or in Combination

NCT00849030

Phase 3 Completed 9358 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

The aim of this study is to test whether Arimidex alone or in combination with Tamoxifen is beneficial in the treatment of breast cancer.

Timeline

Start
1996-07
Primary completion
2001-06
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Anastozole Unknown 1 mg Oral
Comparator Tamoxifen Small molecule 20 mg Oral

Indications